文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

泌尿肿瘤手术前哨淋巴结分期:影像、术中检测与转化研究进展

Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra-operative detection and translational research.
PubMed 文献 · BJU Int · 2025-07-12

本文综述了前哨淋巴结活检(SLNB)在阴茎癌、膀胱癌、前列腺癌、睾丸癌和肾细胞癌中的临床应用、结局与未来方向。在阴茎癌中SLNB不良事件率低于腹股沟淋巴结清扫,灵敏度达92%-96%;在前列腺癌中灵敏度达95%;在肾癌、膀胱癌和睾丸癌中仍在试验探索。

要点

  • 阴茎癌SLNB较腹股沟淋巴结清扫不良事件率更低,灵敏度92%-96%。
  • 前列腺癌SLNB灵敏度达95%,可能强化淋巴结分期并指导个体化治疗。
  • 肾癌、膀胱癌和睾丸癌中SLNB尚处研究阶段,检出率与假阴性率不一。

核心结论

  • SLNB已改变阴茎癌的淋巴结分期,影响治疗决策并降低手术患者并发症。
  • 在其他泌尿恶性肿瘤中,SLNB尚未成为淋巴结分期的标准工具。
  • SLNB对生存、生活质量和转化研究的影响尚待确定。

研究设计与样本

  • 在PubMed和EMBASE检索2000至2024年发表的文献,对泌尿肿瘤学中SLNB进行叙述性综述。

主要发现

  • 阴茎癌中SLNB不良事件率低于腹股沟淋巴结清扫,识别腹股沟淋巴结转移的灵敏度为92%-96%。
  • 前列腺癌中SLNB灵敏度达95%,可能强化其在淋巴结分期和指导个体化治疗策略中的作用。
  • 肾细胞癌中SLNB检出率似乎可接受;膀胱癌和睾丸癌中检出率与假阴性率不一,限制其临床实用性。
  • 当代方法使用多种放射性示踪剂、(荧光)染料和混合示踪剂进行SLNB。
  • 正在研究优化肿瘤靶向淋巴结检测,包括前列腺癌中靶向前列腺特异性膜抗原、阴茎癌中潜在靶向c-MET以及肾细胞癌中89Zr-girentuximab。

临床怎么用

  • 阴茎癌手术患者可考虑SLNB以降低淋巴结清扫相关并发症并维持高检出率。
  • 前列腺癌中SLNB灵敏度高,可用于淋巴结分期和指导个体化治疗策略。
  • 肾癌、膀胱癌和睾丸癌中SLNB的临床应用需等待试验结果,目前不作为标准。

局限性

  • 膀胱癌和睾丸癌中SLNB检出率和假阴性率不一,限制其临床实用性。
  • SLNB对生存、生活质量和转化研究的影响尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To review the clinical utility, outcome and possible future applications of sentinel lymph node biopsy (SLNB) in penile cancer (PeC), bladder cancer (BCa), prostate cancer (PCa), testicular cancer (TCa) and renal cell carcinoma (RCC), focusing in particular on current SLNB standards and exploring advancements in imaging agents, intra-operative detection, surgical navigation, and the potential application of SLNB in translational and clinical research. METHODS: A literature search was conducted in PubMed and EMBASE for studies published between 2000 and 2024, providing a narrative review of SLNB in oncological urology. RESULTS: In PeC, SLNB offers a lower adverse event rate compared to inguinal lymph node (LN) dissection, while maintaining high detection rates and acceptable sensitivity (92%-96%) for identifying inguinal LN metastases. Similarly, in PCa, SLNB achieves a sensitivity of 95%, potentially reinforcing its role in nodal staging and guiding personalised treatment strategies. For RCC, BCa and TCa, SLNB is currently under investigation in trials. In RCC, detection rates seem acceptable; however, in BCa and TCa, detection rates and false-negative rates vary, limiting its clinical usefulness. Contemporary approaches utilise various radiotracers, (fluorescent) dyes, and hybrid tracers for SLNB. Ongoing research refines tumour-targeted LN detection, including prostate-specific membrane antigen targeting in PCa, potential c-MET targeting in PeC, and 89Zr-girentuximab in RCC. CONCLUSION: The use of SLNB has transformed nodal staging in PeC, influencing treatment decisions and reducing morbidity in patients undergoing surgery. In other urological malignancies, it has not yet established itself as a standard tool for nodal staging. Its impact on survival, quality of life, and translational research remains to be determined.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. van Gennep EJ, KleinJan GH, Kuusk T, et al. Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra-operative detection and translational research. BJU Int. 2025. PMID: 40650565. doi:10.1111/bju.16848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。